Opinion: Why the FDA Should Not Approve an Ineffective Multicancer Screening Test

Medical expert H. Gilbert Welch argues against FDA approval of Grail's multicancer screening test, emphasizing that detecting more cancer cases does not constitute medical progress. True progress requires reducing cancer mortality rates, not simply increasing diagnoses. The test's effectiveness in actually saving lives remains questionable, raising concerns about potential overdiagnosis and unnecessary patient anxiety. Healthcare policy experts stress that screening tests must demonstrate clear benefits in reducing deaths before widespread implementation, protecting patients from harm and ensuring resources are used efficiently.